vTv Therapeutics Inc. Class A Share Price
NASDAQ: VTVT | Micro CapvTv Therapeutics Inc. Class A Stock Performance
Open $31.46 | Prev. Close $33.61 | Circuit Range N/A |
Day Range $31.42 - $31.46 | Year Range $18.40 - $42.79 | Volume 981 |
Average Traded $31.43 |
vTv Therapeutics Inc. Class A Share Price Today
As of 13 August 2026, vTv Therapeutics Inc. Class A's share price is $31.59. The stock opened at $31.46, compared to its previous close of $33.61. During today's trading session, vTv Therapeutics Inc. Class A's share price traded between $31.42 and $31.46, with an average price of $31.44. Over the past 52 weeks, the stock has recorded a high of $42.79 and a low of $18.40. In terms of performance, vTv Therapeutics Inc. Class A's share price has declined by 16.35% over the last six months and is up 116.74% on a year-on-year basis.
vTv Therapeutics Inc. Class A Share Price Chart
vTv Therapeutics Inc. Class A Stock Fundamentals & Key Indicators
Market Cap $266.10M | PE Ratio (TTM) -9.87 | Dividend Yield N/A |
EPS (TTM) $-3.20 | Revenue (TTM) N/A | Return On Equity (TTM) -48.23% |
Profit Margin N/A | Debt to Equity 0.10 | Quarterly Earnings Growth YoY -81.85% |
vTv Therapeutics Inc. Class A Quarterly Profit & Loss
All figures in USD
vTv Therapeutics Inc. Class A Annual Profit & Loss
All figures in USD
About vTv Therapeutics Inc. Class A
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
vTv Therapeutics Inc. Class A Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $32.34 | $33.61 | +3.61% |
Jul 2026 | $37.13 | $32.44 | -13.75% |
Jun 2026 | $33.34 | $37.61 | +13.94% |
May 2026 | $31.50 | $33.01 | +3.11% |
Apr 2026 | $40.85 | $32.02 | -16.53% |
Mar 2026 | $35.66 | $38.35 | +1.56% |
Feb 2026 | $37.00 | $37.77 | +6.08% |
Jan 2026 | $42.55 | $35.60 | -9.83% |
Dec 2025 | $26.96 | $39.48 | +45.15% |
Nov 2025 | $20.45 | $27.20 | +27.04% |
Oct 2025 | $22.56 | $21.41 | -6.71% |
Sep 2025 | $18.40 | $22.95 | +57.46% |
VTVT Share Price FAQs
What is vTv Therapeutics Inc. Class A share price today?
What is the 52 week high and 52 week low of vTv Therapeutics Inc. Class A stock?
What is VTVT's market capitalisation today?
What is VTVT's net income for the last quarter?
What is the 5 year returns of VTVT?
What is the high & low stock price of VTVT today?
Can I buy VTVT shares in India?